364793-65-7Relevant articles and documents
Novel quinazoline-containing compound, and intermediate and application thereof
-
, (2021/06/12)
The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.
Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles.
Boschelli, Diane H,Wang, Daniel Y,Ye, Fei,Yamashita, Ayako,Zhang, Nan,Powell, Dennis,Weber, Jennifer,Boschelli, Frank
, p. 2011 - 2014 (2007/10/03)
Based on a screening lead from a yeast-based assay to identify Src family kinase inhibitors, a series of 4-anilino-7-thienyl-3-quinolinecarbonitriles was prepared. When the thiophene ring was substituted with a water-solubilizing group in a 2,5-, 3,5- or 2,4-pattern, potent inhibition of Src kinase activity was observed.